Jeffrey Lieberman, M.D., the Thad and Alice Eure distinguished professor of psychiatry, pharmacology, and radiology and vice chair for research and scientific affairs at the University of North Carolina School of Medicine, is directing the National Institute of Mental Health's CATIE study, which is charged specifically with determining the effectiveness of the various antipsychotic medications (Psychiatric News, May 18).
Grouped together because their primary pharmacologic activity generally involves 5HT2A (serotonergic) and D2 (dopaminergic) receptors, the five atypical antipsychotic medications now licensed in the United States have mechanisms of action that, though still not completely understood, apparently differ markedly. "These medications," Lieberman, a corresponding member of APA's Committee on Research on Psychiatric Treatments, told Psychiatric News, "allow significant changes and improvements in patients' lives, as well as the lives of their families.
agreed.Patients in general, he
told Psychiatric News
, are somewhat dissatisfied with their treatment options for various reasons,some for efficacy reasons, some for safety and tolerability reasons.Regardless of the reason, patients are very interested, he
said, in new options.